ACTR-43. GENOMIC ANALYSIS OF RESPONDERS OF PHASE II TRIAL OF TEMOZOLOMIDE AND TRC-102 (BASE EXCISION REPAIR INHIBITOR) IN BEVACIZUMAB-NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE

BACKGROUND: Temozolomide forms O(6)-methylguanine (O(6)mG), 7-methylguanine (N(7)mG), and 3- methyladenine (N(3)mA) DNA adducts. The O(6)mG DNA adduct is repaired by MGMT. N(7)mG and N(3)mA DNA adducts are removed by the base excision repair (BER) pathway, initiated by N- methylpurine DNA glycosolas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Ahluwalia, Manmeet, Dhruv, Harshil, Fallah, Jaleh, Berens, Michael, Drappatz, Jan, Ye, Xiaobu, Lesser, Glenn, Cloughesy, Timothy, Walbert, Tobias, Holdhoff, Matthias, Peereboom, David, Nabors, Louis, Wen, Patrick, Grossman, Stuart, Rogers, Lisa
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Adult Clinical Trials - Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847634/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.085
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados